{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:37:50Z","timestamp":1785263870622,"version":"3.55.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.pbb.2023.173589","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T02:06:13Z","timestamp":1687226773000},"page":"173589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Epigenetic regulation of metabotropic glutamate 2\/3 receptors: Potential role for ultra-resistant schizophrenia?"],"prefix":"10.1016","volume":"229","author":[{"given":"Francesco","family":"Matrisciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.31887\/DCNS.2014.16.3\/sakbarian","article-title":"Epigenetic mechanisms in schizophrenia","volume":"16","author":"Akbarian","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.biopsych.2010.05.028","article-title":"Early life programming and neurodevelopmental disorders","volume":"68","author":"Bale","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0015","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.neubiorev.2010.10.005","article-title":"Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia","volume":"35","author":"Balu","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.pbb.2023.173589_bb0020","doi-asserted-by":"crossref","first-page":"e6591","DOI":"10.1371\/journal.pone.0006591","article-title":"Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons","volume":"4","author":"Battaglia","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0030","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1471-4159.2005.03456.x","article-title":"Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems","volume":"95","author":"Boldyrev","year":"2005","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pneurobio.2010.09.003","article-title":"The environment and susceptibility to schizophrenia","volume":"93","author":"Brown","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","article-title":"Prenatal infection and schizophrenia: a review of epidemiologic and translational studies","volume":"167","author":"Brown","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2023.173589_bb0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00004647-200109000-00001","article-title":"Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs","volume":"21","author":"Bruno","year":"2001","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.pbb.2023.173589_bb0050","doi-asserted-by":"crossref","unstructured":"Buckley PF. Neuroinflammation and Schizophrenia. Curr. Psychiatry Rep. 2019;21(8):72. (Published 2019 Jul 3). doi:https:\/\/doi.org\/10.1007\/s11920-019-1050-z.","DOI":"10.1007\/s11920-019-1050-z"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"Caraci","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2023.173589_bb0060","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.neuropharm.2004.08.018","article-title":"The mGlu2\/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis","volume":"47","author":"Carter","year":"2004","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pbb.2023.173589_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0014-2999(00)00423-4","article-title":"The mGlu(2\/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing","volume":"400","author":"Cartmell","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2023.173589_bb0070","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0075","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MY20096AH1C","article-title":"Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options","volume":"82","author":"Correll","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0080","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mi.3.4.220","article-title":"Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention?","volume":"3","author":"Costa","year":"2003","journal-title":"Mol. Interv."},{"key":"10.1016\/j.pbb.2023.173589_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2017.10.026","article-title":"Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system","volume":"128","author":"Di Menna","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2023.173589_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.06.020","article-title":"Alterations in cortical interneurons and cognitive function in schizophrenia","volume":"131","author":"Dienel","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/molpharm.121.000460","article-title":"Metabotropic glutamate receptors as emerging targets for the treatment of schizophrenia","volume":"101","author":"Dogra","year":"2022","journal-title":"Mol. Pharmacol."},{"issue":"Pt B","key":"10.1016\/j.pbb.2023.173589_bb0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","article-title":"The kynurenine pathway in schizophrenia and bipolar disorder","volume":"112","author":"Erhardt","year":"2017","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pbb.2023.173589_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coph.2018.01.010","article-title":"Targeting metabotropic glutamate receptors for the treatment of neuroinflammation","volume":"38","author":"Fazio","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173589_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fncir.2018.00037","article-title":"PV interneurons: critical regulators of E\/I balance for prefrontal cortex-dependent behavior and psychiatric disorders","volume":"12","author":"Ferguson","year":"2018","journal-title":"Front. Neural. Circuits"},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb5000","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/mp.2012.199","article-title":"Markers of inflammation in the prefrontal cortex of individuals with schizophrenia","volume":"18","author":"Fillman","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173589_bb0115","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/mp.2015.90","article-title":"Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca\u2019s area volume","volume":"21","author":"Fillman","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173589_bb0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00406-018-0908-0","article-title":"Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort","volume":"269","author":"Fond","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2023.173589_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eurpsy.2017.09.007","article-title":"Regulation of inflammatory pathways in schizophrenia: a comparative study with bipolar disorder and healthy controls","volume":"47","author":"Garc\u00eda-\u00c1lvarez","year":"2018","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/schbul\/sbt001","article-title":"Pro-\/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia","volume":"40","author":"Garc\u00eda-Bueno","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0135","first-page":"153","article-title":"An update on promising biomarkers in schizophrenia","volume":"16","author":"Goldsmith","year":"2018","journal-title":"Focus (Am. Psychiatr. Publ.)"},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0140","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/schbul\/sbn070","article-title":"GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia","volume":"34","author":"Gonzalez-Burgos","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pbb.2023.173589_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/723184","article-title":"GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia","volume":"2011","author":"Gonzalez-Burgos","year":"2011","journal-title":"Neural Plast."},{"issue":"12","key":"10.1016\/j.pbb.2023.173589_bb0150","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biopsych.2015.03.010","article-title":"Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia","volume":"77","author":"Gonzalez-Burgos","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"7183","key":"10.1016\/j.pbb.2023.173589_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0160","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/epi.10.22","article-title":"Schizophrenia and the epigenetic hypothesis","volume":"2","author":"Grayson","year":"2010","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-005-2212-8","article-title":"GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon","volume":"180","author":"Guidotti","year":"2005","journal-title":"Psychopharmacology"},{"issue":"7\u20138","key":"10.1016\/j.pbb.2023.173589_bb0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","article-title":"Epigenetic GABAergic targets in schizophrenia and bipolar disorder","volume":"60","author":"Guidotti","year":"2011","journal-title":"Neuropharmacology"},{"issue":"7\u20138","key":"10.1016\/j.pbb.2023.173589_bb0175","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","article-title":"Epigenetic GABAergic targets in schizophrenia and bipolar disorder","volume":"60","author":"Guidotti","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2023.173589_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1101\/sqb.2004.69.67","article-title":"The (dual) origin of epigenetics","volume":"69","author":"Haig","year":"2004","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0185","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00213-018-5118-y","article-title":"Chronic treatment with a metabotropic mGlu2\/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen","volume":"236","author":"Halberstadt","year":"2019","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pbb.2023.173589_bb0190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41582-021-00530-8","article-title":"Maternal immune activation and neuroinflammation in human neurodevelopmental disorders","volume":"17","author":"Han","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0195","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1523\/JNEUROSCI.2331-12.2013","article-title":"Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system","volume":"33","author":"Holloway","year":"2013","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0200","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2015.2966","article-title":"The role of clozapine in treatment-resistant schizophrenia","volume":"73","author":"Kane","year":"2016","journal-title":"JAMA Psychiatry."},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0210","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YCO.0b013e32835035b2","article-title":"Glutamatergic transmission in schizophrenia: from basic research to clinical practice","volume":"25","author":"Kantrowitz","year":"2012","journal-title":"Curr. Opin. Psychiatry."},{"key":"10.1016\/j.pbb.2023.173589_bb0215","doi-asserted-by":"crossref","unstructured":"Kantrowitz, J. T., Grinband, J., Goff, D. C., Lahti, A. C., Marder, S. R., Kegeles, L. S., Girgis, R. R., Sobeih, T., Wall, M. M., Choo, T. H., Green, M. F., Yang, Y. S., Lee, J., Horga, G., Krystal, J. H., Potter, W. Z., Javitt, D. C., & Lieberman, J. A. (2020). Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology, 45(11), 1842\u20131850. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/s41386-020-0706-z.","DOI":"10.1038\/s41386-020-0706-z"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0220","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2023.173589_bb0225","doi-asserted-by":"crossref","unstructured":"Kinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015). Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol. Psychiatry, 78(11), 754\u2013762. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.biopsych.2015.03.016.","DOI":"10.1016\/j.biopsych.2015.03.016"},{"issue":"9","key":"10.1016\/j.pbb.2023.173589_bb0230","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2023.173589_bb0235","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nn.3181","article-title":"HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity","volume":"15","author":"Kurita","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.pbb.2023.173589_bb0240","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/mol.112.084582","article-title":"Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice","volume":"83","author":"Kurita","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0245","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bph.13364","article-title":"Microglial activation and progressive brain changes in schizophrenia","volume":"173","author":"Laskaris","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389203711314010005","article-title":"Neurotransmitters and microglial-mediated neuroinflammation","volume":"14","author":"Lee","year":"2013","journal-title":"Curr. Protein Pept. Sci."},{"issue":"8","key":"10.1016\/j.pbb.2023.173589_bb0255","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/bph.15570","article-title":"Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders","volume":"179","author":"Leite","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0260","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"6","key":"10.1016\/j.pbb.2023.173589_bb0265","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.biopsych.2017.12.006","article-title":"Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"84","author":"Lin","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173589_bb0270","doi-asserted-by":"crossref","unstructured":"\u013dupt\u00e1k M, Michali\u010dkov\u00e1 D, Fi\u0161ar Z, Kitzlerov\u00e1 E, Hroudov\u00e1 J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J. Psychiatry. 2021;11(7):277\u2013296. (Published 2021 Jul 19). doi:https:\/\/doi.org\/10.5498\/wjp.v11.i7.277.","DOI":"10.5498\/wjp.v11.i7.277"},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1568007024606177","article-title":"Preclinical pharmacology of mGlu2\/3 receptor agonists: novel agents for schizophrenia?","volume":"1","author":"Schoepp","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","article-title":"Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex","volume":"292","author":"Marek","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0285","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/npp.2011.274","article-title":"Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice","volume":"37","author":"Matrisciano","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2023.173589_bb0290","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2012.04.013","article-title":"Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice","volume":"68","author":"Matrisciano","year":"2013","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pbb.2023.173589_bb0295","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2012.04.013","article-title":"Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice","volume":"68","author":"Matrisciano","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb2000","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1570159X13666150713174242","article-title":"Metabotropic Glutamate 2\/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review","volume":"14","author":"Matrisciano","year":"2016","journal-title":"Curr Neuropharmacol."},{"key":"10.1016\/j.pbb.2023.173589_bb0300","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fnmol.2018.00423","article-title":"Epigenetic alterations in prenatal stress mice as an endophenotype model for schizophrenia: role of metabotropic glutamate 2\/3 receptors","volume":"11","author":"Matrisciano","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.pbb.2023.173589_bb0310","article-title":"Neurobiological and systemic effects of chronic stress","volume":"1","author":"McEwen","year":"2017","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"10.1016\/j.pbb.2023.173589_bb0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.pbb.2023.173589_bb0320","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuropharm.2012.11.015","article-title":"An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy","volume":"68","author":"Millan","year":"2013","journal-title":"Neuropharmacology."},{"issue":"7","key":"10.1016\/j.pbb.2023.173589_bb0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5381","key":"10.1016\/j.pbb.2023.173589_bb0330","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0340","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3945\/an.116.014209","article-title":"Early-life nutritional programming of cognition-the fundamental role of epigenetic mechanisms in mediating the relation between early-life environment and learning and memory process","volume":"8","author":"Moody","year":"2017","journal-title":"Adv. Nutr."},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0345","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1523\/JNEUROSCI.4230-10.2011","article-title":"Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT\u2082A and mGlu\u2082 receptors in the adult offspring","volume":"31","author":"Moreno","year":"2011","journal-title":"J. Neurosci."},{"issue":"53","key":"10.1016\/j.pbb.2023.173589_bb0350","doi-asserted-by":"crossref","first-page":"44301","DOI":"10.1074\/jbc.M112.413161","article-title":"Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A\u00b7mGlu2) receptor heteromerization and its psychoactive behavioral function","volume":"287","author":"Moreno","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0355","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0360","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pbb.2023.173589_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2012.10.022","article-title":"The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia","volume":"48","author":"Na","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"7\u20138","key":"10.1016\/j.pbb.2023.173589_bb0370","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2023.173589_bb0375","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fpsyt.2019.00049","article-title":"Targeting mGlu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia","volume":"10","author":"Nicoletti","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0380","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/YCO.0000000000000697","article-title":"Cancer and schizophrenia","volume":"34","author":"Nordentoft","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173589_bb0385","doi-asserted-by":"crossref","unstructured":"O'Donnell, P., Dong, C., Murthy, V., Asgharnejad, M., Du, X., Summerfelt, A., Lu, H., Xu, L., Wendland, J. R., Dunayevich, E., Buhl, D. L., Litman, R., Hetrick, W. P., Hong, L. E., & Rosen, L. B. (2023). The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacology, 48(7), 1052\u20131059. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/s41386-023-01560-0.","DOI":"10.1038\/s41386-023-01560-0"},{"issue":"9690","key":"10.1016\/j.pbb.2023.173589_bb0390","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"10039","key":"10.1016\/j.pbb.2023.173589_bb0395","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2023.173589_bb0400","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/7854_2019_91","article-title":"Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia","volume":"44","author":"Pandurangi","year":"2020","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"9","key":"10.1016\/j.pbb.2023.173589_bb0405","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial [published correction appears in Nat Med. 2007 Oct;13(10):1264]","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0028-3908(94)00129-G","article-title":"The metabotropic glutamate receptors: structure and functions","volume":"34","author":"Pin","year":"1995","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr."},{"issue":"10","key":"10.1016\/j.pbb.2023.173589_bb0420","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pbb.2023.173589_bb0425","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pbb.2023.173589_bb0430","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.pbb.2023.173589_bb0435","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fnmol.2018.00414","article-title":"Metabotropic glutamate receptors in glial cells: a new potential target for neuroprotection?","volume":"11","author":"Spampinato","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.pbb.2023.173589_bb0440","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coph.2018.02.003","article-title":"The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia","volume":"38","author":"Stansley","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2023.173589_bb0445","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.pbb.2023.173589_bb0450","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1523\/JNEUROSCI.4456-04.2005","article-title":"Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand","volume":"25","author":"Taylor","year":"2005","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0455","first-page":"181","article-title":"Nuclear receptors and neuroinflammation in schizophrenia","volume":"3","author":"Tsai","year":"2018","journal-title":"Mol. Neuropsychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2023.173589_bb0460","doi-asserted-by":"crossref","first-page":"e1284","DOI":"10.4088\/JCP.17m11523","article-title":"Anticholinergic burden and cognition in older patients with schizophrenia","volume":"78","author":"Tsoutsoulas","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173589_bb0465","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.neubiorev.2006.04.001","article-title":"Reelin down-regulation in mice and psychosis endophenotypes","volume":"30","author":"Tueting","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0470","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tics.2009.12.002","article-title":"Neural synchrony and the development of cortical networks","volume":"14","author":"Uhlhaas","year":"2010","journal-title":"Trends Cogn. Sci."},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0475","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.pbb.2023.173589_bb0480","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0034-1383656","article-title":"Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.pbb.2023.173589_bb0485","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0074-7742(07)82003-4","article-title":"Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation","volume":"82","author":"Vesce","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"issue":"2","key":"10.1016\/j.pbb.2023.173589_bb0490","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-003-1636-2","article-title":"Serotonergic\/glutamatergic interactions: the effects of mGlu2\/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli","volume":"172","author":"Winter","year":"2004","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2023.173589_bb0495","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pbb.2023.173589_bb0500","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/aps.2017.172","article-title":"GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia","volume":"39","author":"Xu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.pbb.2023.173589_bb0505","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.npp.1300013","article-title":"Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex","volume":"28","author":"Zhai","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"39","key":"10.1016\/j.pbb.2023.173589_bb0510","doi-asserted-by":"crossref","first-page":"13130","DOI":"10.1523\/JNEUROSCI.1039-10.2010","article-title":"Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus","volume":"30","author":"Zhang","year":"2010","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2023.173589_bb0515","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ijnp\/pyaa020","article-title":"Epigenetic modifications of GABAergic interneurons contribute to deficits in adult hippocampus neurogenesis and depression-like behavior in prenatally stressed mice","volume":"23","author":"Zhong","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2023.173589_bb0520","doi-asserted-by":"crossref","unstructured":"Zinni M, Mairesse J, Pansiot J, et al. mGlu3 receptor regulates microglial cell reactivity in neonatal rats. J. Neuroinflammation 2021;18(1):13. (Published 2021 Jan 6). doi:https:\/\/doi.org\/10.1186\/s12974-020-02049-z.","DOI":"10.1186\/s12974-020-02049-z"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572300076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572300076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:45:38Z","timestamp":1758775538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009130572300076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":105,"alternative-id":["S009130572300076X"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173589","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic regulation of metabotropic glutamate 2\/3 receptors: Potential role for ultra-resistant schizophrenia?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173589"}}